Introduction: Two classes of biologics, anti-tumor necrosis factor (TNF) and non-anti-TNF
targeted, are currently available for the treatment of rheumatic diseases. Areas covered …

Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

OBJECTIVE: To determine the prevalence of severe infections in patients with rheumatoid
arthritis (RA) prescribed leflunomide in North Canterbury, New Zealand. METHODS: A case …

Introduction: Teriflunomide is an immunomodulatory drug that received FDA approval for the
treatment of relapsing forms of multiple sclerosis (MS) in September 2012. Its primary mode …

Immunosuppressive therapies are currently indicated for a wide range of diseases. As new
agents emerge and indications evolve the landscape grows increasingly complex …

Objectives To determine the risk of severe infection requiring or complicating hospitalization
associated with leflunomide therapy in patients with rheumatoid arthritis (RA). Methods We …

Background The high discontinuation rate in RA patients who use LEF might be attributed to
their intolerance rather than irresponsibility. The concomitant administration of Leflunomide …

Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been in routine
clinical use for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis for a decade …

Objective To investigate risk factors and characteristics of active tuberculosis (TB) in biologic-
naïve patients with rheumatoid arthritis (RA). Methods We conducted a population-based …

Discussion Pulmonary infection due to atypical organisms is an important cause of illness in
immunocompromised patients. Although still rare, the zoonotic transmission of organisms is …